Location: Special Hospital Medico (Rijeka)
Study Drug: Experimental drug that blocks the FLAP enzyme in lung cells. This protein is responsible for the increased release of molecules that promote inflammation in individuals with asthma.
Main Inclusion Criteria: Patients aged 18-55 who have had one episode of asthma exacerbation in the past year, leading them to visit a doctor, and have been on a stable dose of inhaled corticosteroids for the last 3 months. Additionally, it is important that patients are non-smokers or have not smoked (including the use of electronic cigarettes) for at least 6 months.
Status: Enrolling patients
Start of patient enrollment: July 2023.
Planned completion of new patient enrollment: March 2025.
